JP2014024874A5 - - Google Patents

Download PDF

Info

Publication number
JP2014024874A5
JP2014024874A5 JP2013231673A JP2013231673A JP2014024874A5 JP 2014024874 A5 JP2014024874 A5 JP 2014024874A5 JP 2013231673 A JP2013231673 A JP 2013231673A JP 2013231673 A JP2013231673 A JP 2013231673A JP 2014024874 A5 JP2014024874 A5 JP 2014024874A5
Authority
JP
Japan
Prior art keywords
tableting
dissolution
improving
composition
magnesium stearate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013231673A
Other languages
English (en)
Other versions
JP2014024874A (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2013231673A priority Critical patent/JP2014024874A/ja
Priority claimed from JP2013231673A external-priority patent/JP2014024874A/ja
Publication of JP2014024874A publication Critical patent/JP2014024874A/ja
Publication of JP2014024874A5 publication Critical patent/JP2014024874A5/ja
Pending legal-status Critical Current

Links

Claims (3)

  1. 組成物を圧縮する打錠工程を含むことを特徴とするオルメサルタンメドキソミル含有錠剤の溶出性改善方法であって、前記打錠工程が、141-400 N/mm 2 の圧力を使用する工程かつ、ステアリン酸マグネシウムを除く成分を混合した後にステアリン酸マグネシウムを加えて混合した組成物を打錠する工程であり、前記溶出率改善が、日本薬局方第14改正の項に記載されている溶出試験法第2法(パドル法)による30分後溶出率結果を打錠用混合末に対して20%以上増加させるものである溶出率改善方法。
  2. 組成物を圧縮する打錠工程を含むことを特徴とするオルメサルタンメドキソミル含有錠剤(但し、結晶セルロース又はトウモロコシデンプンを含有する錠剤を除く)の溶出性改善方法であって、前記打錠工程が、60-400 N/mm2の圧力を使用する工程であり、ステアリン酸マグネシウムを除く成分を混合した後ステアリン酸マグネシウムを加えて混合した組成物を打錠する工程である方法。
  3. 組成物が、溶出改善剤を含む請求項1又は請求項2のいずれかに記載の溶出性改善方法。
JP2013231673A 2006-06-27 2013-11-08 圧縮製剤 Pending JP2014024874A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2013231673A JP2014024874A (ja) 2006-06-27 2013-11-08 圧縮製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006176146 2006-06-27
JP2006176146 2006-06-27
JP2013231673A JP2014024874A (ja) 2006-06-27 2013-11-08 圧縮製剤

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2008522575A Division JP5769362B2 (ja) 2006-06-27 2007-06-26 圧縮製剤

Publications (2)

Publication Number Publication Date
JP2014024874A JP2014024874A (ja) 2014-02-06
JP2014024874A5 true JP2014024874A5 (ja) 2014-08-07

Family

ID=38845498

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008522575A Active JP5769362B2 (ja) 2006-06-27 2007-06-26 圧縮製剤
JP2013231673A Pending JP2014024874A (ja) 2006-06-27 2013-11-08 圧縮製剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2008522575A Active JP5769362B2 (ja) 2006-06-27 2007-06-26 圧縮製剤

Country Status (9)

Country Link
US (1) US20100237530A1 (ja)
EP (1) EP2033643A4 (ja)
JP (2) JP5769362B2 (ja)
KR (1) KR101628028B1 (ja)
CN (1) CN101478966B (ja)
BR (1) BRPI0713371A2 (ja)
CA (1) CA2656181C (ja)
TW (1) TWI492747B (ja)
WO (1) WO2008001734A1 (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5554699B2 (ja) * 2008-03-13 2014-07-23 第一三共株式会社 オルメサルタンメドキソミルを含む製剤の溶出性の改善
JP2011136908A (ja) * 2009-12-25 2011-07-14 Kyowa Yakuhin Kogyo Kk アンギオテンシンii受容体拮抗剤を含む固形製剤および固形製剤におけるアンギオテンシンii受容体拮抗剤の保存安定性向上方法
CN102119930B (zh) * 2010-07-13 2013-01-30 福建天泉药业股份有限公司 一种奥美沙坦酯片及制备方法
EP2425859A1 (en) 2010-08-08 2012-03-07 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Olmesartan formulations
CN102028663B (zh) * 2010-12-14 2011-11-30 北京万生药业有限责任公司 一种稳定的奥美沙坦酯固体制剂
DK2830618T3 (en) * 2012-03-30 2016-10-03 Dae Woong Pharma A pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt
CN105663070A (zh) * 2014-11-21 2016-06-15 深圳信立泰药业股份有限公司 一种含有奥美沙坦酯的药物组合物及其制备方法
CN105640913B (zh) * 2016-01-22 2018-11-02 山东省医学科学院药物研究所 一种奥美沙坦酯片及其制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3096248A (en) * 1959-04-06 1963-07-02 Rexall Drug & Chemical Company Method of making an encapsulated tablet
JPH0282519A (ja) 1988-09-19 1990-03-23 Sanyo Electric Co Ltd 固相エピタキシャル成長方法
US5616599A (en) * 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
JPH0624959A (ja) * 1991-10-04 1994-02-01 Bayer Yakuhin Kk 胃内浮遊型薬物徐放性固形製剤
US5298261A (en) * 1992-04-20 1994-03-29 Oregon Freeze Dry, Inc. Rapidly distintegrating tablet
US6465009B1 (en) * 1998-03-18 2002-10-15 Yamanouchi Pharmaceutical Co., Ltd. Water soluble polymer-based rapidly dissolving tablets and production processes thereof
DE69928110T2 (de) * 1998-07-15 2006-07-27 Asahi Kasei Chemicals Corporation Trägerhilfstoff
JP3796562B2 (ja) * 1999-05-26 2006-07-12 ライオン株式会社 多層錠、多層錠の製造方法及び多層錠の剥離抑制方法
BR0112124B1 (pt) * 2000-07-05 2011-06-14 pà de celulose, processo para produzir um pà de celulose, excipiente, e, produto moldado.
JP2002167327A (ja) * 2000-09-22 2002-06-11 Takeda Chem Ind Ltd 固形製剤
US20040132731A1 (en) * 2002-06-26 2004-07-08 Fox David Nathan Abraham Novel combination
NZ541454A (en) * 2003-01-31 2008-04-30 Daiichi Sankyo Co Ltd Medicine for prevention of and treatment for arteriosclerosis and hypertension
CA2532450C (en) 2003-07-16 2012-09-11 Boehringer Ingelheim International Gmbh Chlorthalidone combinations
ES2688193T3 (es) * 2003-10-15 2018-10-31 Fuji Chemical Industry Co., Ltd. Comprimido de disgregación rápida en la cavidad oral
GB0325291D0 (en) * 2003-10-29 2003-12-03 Pfizer Ltd Novel combination
AU2004285354B2 (en) * 2003-10-31 2009-09-17 Takeda Pharmaceutical Company Limited Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester
CA2575177A1 (en) 2004-09-02 2006-03-16 Teva Pharmaceutical Industries Ltd. Purification of olmesartan medoxomil
WO2007001067A2 (en) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Solid dosage form comprising an angiotensin ii receptor antagonist and a calcium channel blocker
US20080279942A1 (en) 2005-06-27 2008-11-13 Takeshi Hamaura Pharmaceutical Preparation Containing an Angiotensin II Receptor Antagonist and a Calcium Channel Blocker
JP5063370B2 (ja) * 2005-06-27 2012-10-31 第一三共株式会社 湿式造粒製薬の調製方法
EP1891952B1 (en) 2006-05-04 2011-10-05 LEK Pharmaceuticals d.d. Pharmaceutical composition of olmesartan medoxomil

Similar Documents

Publication Publication Date Title
JP2014024874A5 (ja)
JP2014167026A5 (ja)
CL2013001586A1 (es) Composicion microgranular de rapida dispersion que comprende al menos un alcohol de azucar, un sacarido, o una mezcla de estos, al menos un super disgregante y al menos un aditivo multifuncion; comprimido de desintegracion oral que comprende la composicion microgranular y al menos un principio activo; y metodos de fabricacion.
EP2600849A4 (en) COMPOSITION FORMING A FILM FOR SOFT CAPSULES
JP2015511635A5 (ja)
JP2017520577A5 (ja)
WO2011104652A3 (en) Veterinary compositions
AU2014271645B2 (en) Oral cavity patch
JP2009542678A5 (ja)
JP2016108327A5 (ja)
WO2008100240A3 (en) Pharmaceutical composition with sodium lauryl sulfate as an extra-granular absorption/compression enhancer and the process to make the same
RU2016117186A (ru) Комбинированная композиция, содержащая тадалафил и амлодипин
HRP20141134T1 (hr) Kruta farmaceutska formulacija
JP2015129124A5 (ja)
JP2014218523A5 (ja)
JP2009091362A5 (ja)
TW200732000A (en) Orally disintegrating table comprising fat-soluble drug
JP2017520619A5 (ja)
JP2016535762A5 (ja)
CN103860508A (zh) 一种盐酸二甲双胍缓释片及其制备方法
RU2018100755A (ru) Комбинированный препарат мозаприда и рабепразола
CN103908435B (zh) 一种氟他胺缓释制剂及其制备方法
WO2011151018A3 (en) Orodispersible tablets of erythritol and isomalt
CN105106963B (zh) 马来酸曲美布汀缓释制剂及其制备方法
CN101461815B (zh) 三氟柳药物组合物及其制备方法